These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17458792)

  • 21. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration.
    Shah AR; Del Priore LV
    Ophthalmology; 2009 Oct; 116(10):1901-7. PubMed ID: 19592101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degeneration.
    Mruthyunjaya P; Stinnett SS; Toth CA
    Ophthalmology; 2004 Sep; 111(9):1715-24. PubMed ID: 15350328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Avila MP; Farah ME; Santos A; Carla L; Fuji G; Rossi J; Nau J
    Retina; 2012 Jan; 32(1):10-8. PubMed ID: 21817963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
    BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
    Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
    Retina; 2006; 26(9):994-8. PubMed ID: 17151485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration.
    Avila MP; Farah ME; Santos A; Duprat JP; Woodward BW; Nau J
    Br J Ophthalmol; 2009 Mar; 93(3):305-9. PubMed ID: 19019935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Intravitreal bevacizumab (Avastin) iniections for neovascular age-related macular degeneration (AMD)--preliminary results].
    Mackiewicz J; Mańkowska A; Dolar-Szczasny J; Zubilewicz A; Oleszczuk A; Nowomiejska K; Rejdak R; Zagórski Z
    Klin Oczna; 2007; 109(4-6):146-9. PubMed ID: 17725273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The predictive value of OCT characteristics for the visual outcome in neovascular AMD.
    Kolb S; Menghini M; Barthelmes D; Sutter F; Kurz-Levin M
    Klin Monbl Augenheilkd; 2012 Apr; 229(4):343-7. PubMed ID: 22496000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Intravitreal injection of bevacizumab for exsudative AMD with occult or minimal classic choroidal neovascularisation (CNV)].
    Maier M; Feucht N; Haas K; Fiore B; Winkler von Mohrenfels C; Clos A; Lohmann C
    Klin Monbl Augenheilkd; 2008 Sep; 225(9):818-24. PubMed ID: 18759214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation.
    Robin AL; Clark AF; Covert DW; Krueger S; Bergamini MV; Landry TA; Dickerson JE; Scheib SA; Realini T; Defaller JM; Cagle GD
    Am J Ophthalmol; 2009 Jan; 147(1):45-50.e2. PubMed ID: 18789793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results.
    Cleary CA; Jungkim S; Ravikumar K; Kelliher C; Acheson RW; Hickey-Dwyer M
    Eye (Lond); 2008 Jan; 22(1):82-6. PubMed ID: 17891059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration].
    Kloos P; Bernasconi P; Estermann S; Bachmann B; Rutishauser Y; Thölen A
    Klin Monbl Augenheilkd; 2008 May; 225(5):385-91. PubMed ID: 18454378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results.
    Carneiro AM; Falcão MS; Brandão EM; Falcão-Reis FM
    Retina; 2010 Jan; 30(1):85-92. PubMed ID: 20010320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study.
    Bashshur ZF; Haddad ZA; Schakal AR; Jaafar RF; Saad A; Noureddin BN
    Am J Ophthalmol; 2009 Jul; 148(1):59-65.e1. PubMed ID: 19375689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results.
    Lee J; Freeman WR; Azen SP; Chung EJ; Koh HJ
    Retina; 2007; 27(9):1205-13. PubMed ID: 18046226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration.
    Geltzer A; Turalba A; Vedula SS
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005022. PubMed ID: 17943833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
    Costa RA; Jorge R; Calucci D; Cardillo JA; Melo LA; Scott IU
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical efficacy of anecortave acetate.
    Clark AF
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S41-8. PubMed ID: 17240256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.